NASDAQ:ORTX - Orchard Therapeutics Stock Price, Forecast & News

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Orchard Therapeutics PLC - (NASDAQ:ORTX) issued its earnings results on Wednesday, November, 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. The firm earned $1.92 million during the quarter, compared to the consensus estimate of $0.53 million. View Orchard Therapeutics' Earnings History.

Orchard Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Orchard Therapeutics.

Orchard Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 equities research analysts have issued 12 month price objectives for Orchard Therapeutics' stock. Their forecasts range from $21.00 to $31.00. On average, they anticipate Orchard Therapeutics' stock price to reach $26.20 in the next year. This suggests a possible upside of 117.6% from the stock's current price. View Analyst Price Targets for Orchard Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orchard Therapeutics.

News coverage about ORTX stock has trended somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Orchard Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Orchard Therapeutics.

Orchard Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totalling 840,300 shares, an increase of 69.0% from the December 31st total of 497,200 shares. Based on an average trading volume of 271,100 shares, the short-interest ratio is presently 3.1 days. Approximately 1.2% of the company's shares are sold short. View Orchard Therapeutics' Current Options Chain.

Some companies that are related to Orchard Therapeutics include China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Allogene Therapeutics (ALLO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC) and Regenxbio (RGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Range Resources (RRC), Callon Petroleum (CPE), Coeur Mining (CDE), Heron Therapeutics (HRTX), Helmerich & Payne (HP), Pfizer (PFE), Alerian MLP ETF (AMLP), Applied Genetic Technologies (AGTC), Alnylam Pharmaceuticals (ALNY) and Apellis Pharmaceuticals (APLS).

(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Orchard Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (12.76%), RA Capital Management L.P. (6.64%), Baillie Gifford & Co. (2.85%), Artisan Partners Limited Partnership (2.80%), Driehaus Capital Management LLC (1.53%) and ArrowMark Colorado Holdings LLC (1.36%). View Institutional Ownership Trends for Orchard Therapeutics.

ORTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Barclays PLC, Bank of America Corp DE and Victory Capital Management Inc.. View Insider Buying and Selling for Orchard Therapeutics.

ORTX stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., RA Capital Management L.P., Artisan Partners Limited Partnership, Casdin Capital LLC, ArrowMark Colorado Holdings LLC, New York State Common Retirement Fund, Marshall Wace LLP and Berylson Capital Partners LLC. View Insider Buying and Selling for Orchard Therapeutics.

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ORTX stock can currently be purchased for approximately $12.04.

Orchard Therapeutics has a market capitalization of $1.16 billion and generates $2.08 million in revenue each year. The company earns $-230,490,000.00 in net income (profit) each year or ($10.22) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe.View Additional Information About Orchard Therapeutics.

The official website for Orchard Therapeutics is http://www.orchard-tx.com/.

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 44-20-3384-6700.